Information Provided By:
Fly News Breaks for March 16, 2015
BAX, CTIC
Mar 16, 2015 | 09:15 EDT
Roth Capital believes that CTI (CTIC) and its partner, Baxter (BAX), reported positive topline results for their Pacritinib drug, Roth Capital believes that comparisons between the Pacritinib trial and a trial of Incyte's (INCY) Jakafi are potentially flawed. The firm says that sicker patients appear not to have been included in Jakafi's trials. Roth says that the data appears to show that Pacritinib is "very competitive." The firm reiterates a $4.50 price target and Buy rating on CTI.
News For CTIC;BAX From the Last 2 Days
There are no results for your query CTIC;BAX